Merck (MRK) Tops Q2 EPS by 12c, Beats on Revenue; Offers FY24 EPS Guidance

Merck (NYSE: MRK) reported Q2 EPS of $2.28, $0.12 better than the analyst estimate of $2.16. Revenue for the quarter came in at $16.11 billion versus the consensus estimate of $15.85 billion.

GUIDANCE:

Merck sees FY2024 EPS of $7.94-$8.04, versus the consensus of $8.16. Merck sees FY2024 revenue of $63.4-64.4 billion, versus the consensus of $64.3 billion.

For earnings history and earnings-related data on Merck (MRK) click here.

You May Also Be Interested In

• Freedom Capital Upgrades Cerebras Systems (CBRS) to Buy
• Hyperscale Data weighs sale or partnership for askROI unit
• Increasing unusual option volume: GFL SDGR QSR KPTI UAA QSI DYN MAT